---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-029955"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:32:08.265043+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Insmed-AstraZeneca negotiation for brensocatib in COPD/asthma expires without agreement

## Summary
- AstraZeneca exercised final option for brensocatib in COPD/asthma on March 8, 2024.
- Negotiation period expired June 12, 2024; no agreement reached.
- Insmed retains full worldwide rights to brensocatib outside COPD/asthma.
- AstraZeneca has no further rights to develop or commercialize brensocatib in any indication.

## SEC filing metadata
- accession: 0001140361-24-029955
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124029955/0001140361-24-029955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124029955/ef20031070_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-029955
- JSON: https://secwatch.observer/filing/0001140361-24-029955.json
- Plain text: https://secwatch.observer/filing/0001140361-24-029955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.